David FitzGerald

1.7k total citations
34 papers, 1.3k citations indexed

About

David FitzGerald is a scholar working on Immunology, Molecular Biology and Biotechnology. According to data from OpenAlex, David FitzGerald has authored 34 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Immunology, 16 papers in Molecular Biology and 14 papers in Biotechnology. Recurrent topics in David FitzGerald's work include Toxin Mechanisms and Immunotoxins (25 papers), Transgenic Plants and Applications (13 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). David FitzGerald is often cited by papers focused on Toxin Mechanisms and Immunotoxins (25 papers), Transgenic Plants and Applications (13 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). David FitzGerald collaborates with scholars based in United States, Hungary and Cameroon. David FitzGerald's co-authors include Ira Pastan, Vijay K. Chaudhary, Yoshihiro Jinno, Mark C. Willingham, Nathan C. Simon, Clay B. Siegall, Ira Pastan, Masanori Onda, Joseph Shiloach and Prem Seth and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David FitzGerald

34 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David FitzGerald United States 19 755 584 437 240 201 34 1.3k
M J Bjorn United States 20 729 1.0× 609 1.0× 392 0.9× 364 1.5× 303 1.5× 27 1.5k
Joan M. Moehring United States 25 794 1.1× 743 1.3× 471 1.1× 92 0.4× 193 1.0× 47 1.7k
G. Jonah Rainey United States 19 332 0.4× 1.1k 1.9× 274 0.6× 326 1.4× 531 2.6× 27 1.7k
Mara Gerloni United States 24 685 0.9× 418 0.7× 142 0.3× 130 0.5× 68 0.3× 62 1.5k
Cheryl Goldbeck United States 10 580 0.8× 597 1.0× 233 0.5× 68 0.3× 130 0.6× 12 1.3k
Guy T. Layton United Kingdom 22 794 1.1× 561 1.0× 74 0.2× 173 0.7× 102 0.5× 50 1.7k
Joyce M. Zarling United States 22 1.2k 1.6× 424 0.7× 161 0.4× 209 0.9× 228 1.1× 26 2.0k
Maria Tagliamonte Italy 27 972 1.3× 764 1.3× 132 0.3× 126 0.5× 143 0.7× 78 2.0k
Linda Gritz United States 23 1.1k 1.5× 1.2k 2.1× 179 0.4× 142 0.6× 586 2.9× 34 2.4k
Christine L. White United States 24 475 0.6× 722 1.2× 198 0.5× 62 0.3× 691 3.4× 46 1.9k

Countries citing papers authored by David FitzGerald

Since Specialization
Citations

This map shows the geographic impact of David FitzGerald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David FitzGerald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David FitzGerald more than expected).

Fields of papers citing papers by David FitzGerald

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David FitzGerald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David FitzGerald. The network helps show where David FitzGerald may publish in the future.

Co-authorship network of co-authors of David FitzGerald

This figure shows the co-authorship network connecting the top 25 collaborators of David FitzGerald. A scholar is included among the top collaborators of David FitzGerald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David FitzGerald. David FitzGerald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peer, Cody J., Xianyu Zhang, Hyoyoung Choo‐Wosoba, et al.. (2024). Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers. Frontiers in Oncology. 14. 1386190–1386190. 3 indexed citations
2.
Ho, Eric, et al.. (2022). Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity. Biomedicine & Pharmacotherapy. 157. 114047–114047. 10 indexed citations
3.
Thomason, Maureen K., Maya Voichek, Daniel Dar, et al.. (2019). A rhlI 5′ UTR-Derived sRNA Regulates RhlR-Dependent Quorum Sensing in Pseudomonas aeruginosa. mBio. 10(5). 40 indexed citations
4.
Ho, Mitchell, et al.. (2018). Generation of antibody-based therapeutics targeting the idiotype of B-cell malignancies. PubMed. 2(1). 12–21. 1 indexed citations
5.
Cornelius, Jack R., Antoine Douaihy, Levent Kirisci, et al.. (2016). A Review Of The Literature Of Mirtazapine In Co-Occurring Depression And An Alcohol Use Disorder. PubMed. 5(4). 2 indexed citations
6.
Sharma, Ashima & David FitzGerald. (2010). Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis. Toxicon. 56(6). 1025–1034. 12 indexed citations
7.
Ho, Mitchell, Tapan K. Bera, Mark C. Willingham, et al.. (2007). Mesothelin Expression in Human Lung Cancer. Clinical Cancer Research. 13(5). 1571–1575. 113 indexed citations
8.
Avramoglu, Rita Kohen, Johannes Nimpf, Roger S. McLeod, et al.. (1998). Functional Expression of the Chicken Low Density Lipoprotein Receptor-related Protein in a Mutant Chinese Hamster Ovary Cell Line Restores Toxicity of Pseudomonas Exotoxin A and Degradation of α2-Macroglobulin. Journal of Biological Chemistry. 273(11). 6057–6065. 20 indexed citations
9.
Pastan, Ira, Lee H. Pai, Ulrich Brinkmann, & David FitzGerald. (1996). Recombinant immunotoxins. Breast Cancer Research and Treatment. 38(1). 3–9. 14 indexed citations
10.
FitzGerald, David. (1996). Why toxins!. Seminars in Cancer Biology. 7(2). 87–95. 21 indexed citations
11.
12.
Theuer, Charles P., David FitzGerald, & Ira Pastan. (1992). A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing.. Journal of Biological Chemistry. 267(24). 16872–16877. 36 indexed citations
13.
Debinski, Waldemar, B. Karlsson, Leif Lindholm, et al.. (1992). Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice.. Journal of Clinical Investigation. 90(2). 405–411. 31 indexed citations
14.
Puri, Raj K., David FitzGerald, Pamela Leland, Robert W. Kozak, & Ira Pastan. (1992). In vitro and in vivo suppression of interleukin-2-activated killer cell activity by chimeric proteins between interleukin-2 and Pseudomonas exotoxin. Cellular Immunology. 143(2). 324–334. 3 indexed citations
15.
Epstein, Stephen E., Clay B. Siegall, Sadatoshi Biro, et al.. (1991). Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells.. Circulation. 84(2). 778–787. 55 indexed citations
16.
FitzGerald, David & I Pastan. (1991). Redirecting Pseudomonas exotoxin.. PubMed. 2(1). 31–7. 13 indexed citations
17.
Puri, Raj K., M Ogata, Pamela Leland, et al.. (1991). Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin.. PubMed. 51(11). 3011–7. 42 indexed citations
18.
Batra, Janendra K., Vijay K. Chaudhary, David FitzGerald, & Ira Pastan. (1990). TGFα-anti-Tac(Fv)-PE40: A bifunctional toxin cytotoxic for cells with EGF or IL2 receptors. Biochemical and Biophysical Research Communications. 171(1). 1–6. 14 indexed citations
19.
Case, John P., Haya Lorberboum‐Galski, Robert Lafyatis, et al.. (1989). Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats.. Proceedings of the National Academy of Sciences. 86(1). 287–291. 42 indexed citations
20.
FitzGerald, David, Randal E. Morris, & Catharine B. Saelinger. (1983). Inhibition of the Activity of Pseudomonas Toxin by Methylamine. Clinical Infectious Diseases. 5(Supplement_5). S985–S991. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M J Bjorn Breakdown of academic impact, for papers by Joan M. Moehring Breakdown of academic impact, for papers by G. Jonah Rainey Breakdown of academic impact, for papers by Mara Gerloni Breakdown of academic impact, for papers by Cheryl Goldbeck Breakdown of academic impact, for papers by Guy T. Layton Breakdown of academic impact, for papers by Joyce M. Zarling Breakdown of academic impact, for papers by Maria Tagliamonte Breakdown of academic impact, for papers by Linda Gritz Breakdown of academic impact, for papers by Christine L. White
Rankless by CCL
2026